公开(公告)号：US20240084288A1

公开(公告)日：2024-03-14

申请号：US18515879

申请日：2023-11-21

Applicant: BioNTech SE

Inventor： Katalin Kariko ,  Ugur Sahin

IPC: C12N15/10 ,  C07K14/505 ,  C12N15/67 ,  C12N15/88 ,  C12P19/34

CPC classification number: C12N15/102 ,  C07K14/505 ,  C12N15/10 ,  C12N15/67 ,  C12N15/88 ,  C12P19/34

Abstract: The present invention relates to RNA therapy and, in particular, decreasing immunogenicity of RNA. Specifically, the present invention provides methods for decreasing immunogenicity of RNA, said methods comprising modifying the nucleotide sequence of the RNA by reducing the uridine (U) content, wherein said reduction of the U content comprises an elimination of U nucleosides from the nucleotide sequence of the RNA and/or a substitution of U nucleosides by nucleosides other than U in the nucleotide sequence of the RNA. Using RNA having decreased immunogenicity allows administration of RNA as a drug to a subject, e.g. in order to obtain expression of a pharmaceutically active peptide or protein, without eliciting an immune response which would interfere with therapeutic effectiveness of the RNA or induce adverse effects in the subject.

公开(公告)号：US11873478B2

公开(公告)日：2024-01-16

申请号：US17012599

申请日：2020-09-04

Applicant: BioNTech SE

Inventor： Katalin Kariko ,  Ugur Sahin

IPC: C12N15/10 ,  C12N15/67 ,  C12P19/34 ,  C12N15/88 ,  C07K14/505

CPC classification number: C12N15/102 ,  C07K14/505 ,  C12N15/10 ,  C12N15/67 ,  C12N15/88 ,  C12P19/34

Abstract: The present invention relates to RNA therapy and, in particular, decreasing immunogenicity of RNA. Specifically, the present invention provides methods for decreasing immunogenicity of RNA, said methods comprising modifying the nucleotide sequence of the RNA by reducing the uridine (U) content, wherein said reduction of the U content comprises an elimination of U nucleosides from the nucleotide sequence of the RNA and/or a substitution of U nucleosides by nucleosides other than U in the nucleotide sequence of the RNA. Using RNA having decreased immunogenicity allows administration of RNA as a drug to a subject, e.g. in order to obtain expression of a pharmaceutically active peptide or protein, without eliciting an immune response which would interfere with therapeutic effectiveness of the RNA or induce adverse effects in the subject.